HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

Fried, Michael W., Piratvisuth, Teerha, Lau, George K. K., Marcellin, Patrick, Chow, Wan-Cheng, Cooksley, Graham, Luo, Kang-Xian, Paik, Seung Woon, Liaw, Yun-Fan, Button, Peter and Popescu, Matei (2008) HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology, 47 2: 428-434. doi:10.1002/hep.22065


Author Fried, Michael W.
Piratvisuth, Teerha
Lau, George K. K.
Marcellin, Patrick
Chow, Wan-Cheng
Cooksley, Graham
Luo, Kang-Xian
Paik, Seung Woon
Liaw, Yun-Fan
Button, Peter
Popescu, Matei
Title HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
Journal name Hepatology   Check publisher's open access policy
ISSN 0270-9139
1527-3350
Publication date 2008-02-01
Sub-type Article (original research)
DOI 10.1002/hep.22065
Open Access Status Not yet assessed
Volume 47
Issue 2
Start page 428
End page 434
Total pages 7
Editor Andres T. Blei
Gregory Bologna
Place of publication Hoboken, NJ, U.S.A.
Publisher John Wiley & Sons, Inc.
Language eng
Subject C1
1103 Clinical Sciences
Formatted abstract
The aims of this study were to evaluate the usefulness of quantitative hepatitis B e antigen (HBeAg) values for predicting HBeAg seroconversion in patients treated with peginterferon alfa-2a and to assess the dynamic changes in quantitative HBeAg during therapy, compared with conventional measures of serum hepatitis B virus DNA. Data were analyzed from a large, randomized, multinational phase III registration trial involving 271 HBV-infected HBeAg-positive patients who received peginterferon alfa-2a plus oral placebo for 48 weeks. HBeAg levels were measured serially during therapy using a microparticle enzyme immunoassay validated with in-house reference standards obtained from the Paul Ehrlich Institute (PEIU/mL). In patients who achieved HBeAg seroconversion, levels of HBeAg consistently decreased during treatment and remained at their lowest level during the 24 weeks of posttreatment follow-up. After 24 weeks of treatment, 4% of patients with the highest levels of HBeAg (≥100 PEIU/mL) achieved HBeAg seroconversion, yielding a negative predictive value of 96%, which was greater than that obtained for levels of HBV DNA (86%). Late responders to peginterferon alfa-2a could also be differentiated from nonresponders by continued decrease in HBeAg values, which were not evident by changes in HBV DNA. Conclusion: These analyses suggest quantitative HBeAg is a useful adjunctive measurement for predicting HBeAg seroconversion in patients treated with peginterferon when considering both sensitivity and specificity compared with serum HBV DNA.
Copyright © 2008 American Association for the Study of Liver Diseases

Keyword HBeAg
Chronic hepatitis B
Cytokine
Hepatic disease
Digestive diseases
Interferon alpha 2a
Pegylated form
Hepadnaviridae
Orthohepadnavirus
Viral disease
Antineoplastic agent
Immunomodulator
Hepatitis B virus
Peginterferon alfa-2a
Viral hepatitis B
Q-Index Code C1
Q-Index Status Confirmed Code

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2009 Higher Education Research Data Collection
Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 157 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 177 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 08 Apr 2009, 19:57:07 EST by Amy Wong on behalf of Medicine - Royal Brisbane and Women's Hospital